27 March 2017

Merck Animal Health Champions Young Aquaculture Leaders with New Salmon Science Award

Call for Submissions Announced; Applications Due by April 7, 2017

MADISON, NJ, March 27, 2017 – Merck Animal Health (known as MSD Animal Health outside the US and Canada) is proud to announce the introduction of the High Quality Salmon Science Award supporting research in salmon health and welfare by tomorrow’s industry leaders. Starting this year, Merck Animal Health will award one recent graduate in veterinary or animal science the opportunity to present their research to an impressive number of industry specialists at an upcoming Merck Animal Health High Quality Salmon meeting in Scotland, UK.

“With growing demand for safe, affordable protein, the salmon industry is working hard to ensure the health and welfare of the stocks they are rearing,” said Dr. Chris Beattie, Head of Aquaculture, Merck Animal Health. “We hope to establish lasting relationships with recent graduates who are leading the way in important research and innovation that will benefit salmon health, production and welfare.”

The winner will present their research project to a group of aquaculture industry specialists at a Merck Animal Health sponsored High Quality Salmon Congress. Topics of interest include parasite challenges and solutions; infectious diseases such as pancreatic disease (PD), Moritella, Cardiopyopathy syndrome (CMS), and Hearth and skeletal muscle inflammation (HSMI); antibiotic reduction; and precision medicine, among others.

To apply, eligible graduates must submit a 300-word summary of their research project, resume and a brief letter describing why their work deserves the award to HQAquaAward@merck.com. Applications must be submitted by April 7, 2017.

The winner will be notified no later than May 1, 2017. For additional details, please visit: http://www.highqualitycongress.com.

About Merck Animal Health
For over a century, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).